CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Squarex Pharmaceutical Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Squarex Pharmaceutical Corp
1000 Westgate Dr, Suite 1010
Phone: (651) 207-8270p:651 207-8270 SAINT PAUL, MN  55114  United States Fax: (845) 818-3588f:845 818-3588
Business Summary
Squarex Pharmaceutical Corporation is a pharmaceutical company. The Company is engaged in developing a late-clinical-stage drug to improve immune function to reduce severity and incidence of infectious disease with an initial focus on oral herpes. The Company's drug SQX770 has completed a Phase I and a Phase II placebo-controlled clinical trial. SQX770 contains the active ingredient squaric acid dibutyl ester (SADBE). The SQX770 drug is topically applied on a patient's arm, not the face or lip or a lesion. In the Phase III trials and commercially, the Company plans to dose patients once every three months.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022-Yes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Chief Scientist HughMctavish 60 1/1/2012 1/1/2012
Chief Financial Officer ConstantineKardaras 65 1/1/2023 1/1/2023
Independent Director Wayne I.Danson 68 11/1/2022 11/1/2022
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 7,354,502 (As of 12/31/2022)
Federal Tax Id: 455576357
Fax Number: (845) 818-3588


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 23, 2024